Pr Tufveson - Corline Biomedical Chief Officer
| CLBIO Stock | SEK 7.08 0.38 5.67% |
Insider
Pr Tufveson is Chief Officer of Corline Biomedical AB
| Phone | 46 18 71 30 90 |
| Web | https://www.corline.se |
Corline Biomedical Management Efficiency
Corline Biomedical's management efficiency ratios could be used to measure how well Corline Biomedical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Clarisa Mogolln | Sedana Medical AB | N/A | |
| Peter MD | Sedana Medical AB | 52 | |
| Anders Ersson | Sedana Medical AB | 54 | |
| Malin | eEducation Albert AB | N/A | |
| Sture Stolen | Norva24 Group AB | N/A | |
| LarsErik Eriksson | Clinical Laserthermia Systems | 74 | |
| Dan Mogren | Clinical Laserthermia Systems | N/A | |
| Sven Kristensen | Mekonomen AB | N/A | |
| Christian Tomadini | Embellence Group AB | N/A | |
| Jonas Martensson | eEducation Albert AB | 39 | |
| Claes Drougge | IAR Systems Group | 63 | |
| Piotr Zysk | Mekonomen AB | N/A | |
| Philipp Mathieu | Immunovia publ AB | N/A | |
| Martin Dahlgren | eEducation Albert AB | 30 | |
| Mikael Blomqvist | KABE Group AB | 42 | |
| Ali Sebt | IAR Systems Group | N/A | |
| Par Ihrskog | Embellence Group AB | N/A | |
| Robert Hrd | Mekonomen AB | 57 | |
| Karin Liwendahl | Immunovia publ AB | 61 | |
| Olle Svensk | Embellence Group AB | 55 | |
| Bertolt Gartner | Norva24 Group AB | 56 | |
Management Performance
| Return On Equity | 0.0075 | |||
| Return On Asset | 0.0044 |
Corline Biomedical Leadership Team
Elected by the shareholders, the Corline Biomedical's board of directors comprises two types of representatives: Corline Biomedical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Corline. The board's role is to monitor Corline Biomedical's management team and ensure that shareholders' interests are well served. Corline Biomedical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Corline Biomedical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Henrik Nittmar, Chief Officer | ||
| Pr Tufveson, Chief Officer |
Corline Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Corline Biomedical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0075 | |||
| Return On Asset | 0.0044 | |||
| Profit Margin | 0.02 % | |||
| Operating Margin | 0.02 % | |||
| Current Valuation | 178.43 M | |||
| Shares Outstanding | 21.49 M | |||
| Shares Owned By Insiders | 54.88 % | |||
| Shares Owned By Institutions | 14.21 % | |||
| Price To Earning | (19.42) X | |||
| Price To Book | 2.20 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Corline Stock Analysis
When running Corline Biomedical's price analysis, check to measure Corline Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corline Biomedical is operating at the current time. Most of Corline Biomedical's value examination focuses on studying past and present price action to predict the probability of Corline Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corline Biomedical's price. Additionally, you may evaluate how the addition of Corline Biomedical to your portfolios can decrease your overall portfolio volatility.